Epstein-Barr virus-associated leukemic lymphoma after allogeneic stem cell transplantation.

Related Articles

Epstein-Barr virus-associated leukemic lymphoma after allogeneic stem cell transplantation.

J Clin Virol. 2016 Jul;80:82-6

Authors: Takamatsu H, Araki R, Nishimura R, Yachie A, Espinoza JL, Okumura H, Yoshida T, Kuzushima K, Nakao S

Abstract
Leukemic Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative diseases (PTLD) following allogeneic hematopoietic stem cell transplantation are extremely rare. We can successfully treat an EBV-associated leukemic lymphoma patient with rituximab, cidofovir, and donor lymphocyte infusion (DLI). In the present case, EBV-specific T cells that were present in the peripheral blood before rituximab administration treatment rapidly increased after DLI in association with a decrease in the EBV-DNA load.

PMID: 27218416 [PubMed - indexed for MEDLINE]

http://ift.tt/2zgSbPu